Sign inJoin waitlistJoin the waitlist

MS

Maria Sulis

Chief, Pediatric Hematologic Malignancies Service · New York Presbyterian Hospital

Credentials: · · ·

History

Pediatric Hematologic Malignancies Service Division · New York Presbyterian Hospital
Present

Pediatric Hematology Oncology
New York Presbyterian Hospital
1996–1999
Pediatrics
New York Medical College
1993–1996
University of Cagliari, Italy
1989–1993

Research

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Nature Medicine · 2007 · 734 citations
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth
Proceedings of the National Academy of Sciences of the United States of America · 2006 · 685 citations
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia
The Journal of Experimental Medicine · 2007 · 390 citations

Lewis Silverman
9 papers
NS
Neerav Shukla
9 papers
Mignon Loh
8 papers
Peter Cole
8 papers
Kara Kelly
7 papers
Todd Cooper
7 papers
Andrew Place
6 papers
JB
Julia Bender
6 papers
Marian Harris
6 papers
Michael Burke
6 papers
Stephen Sallan
6 papers
Barbara Asselin
5 papers

Clinical trials

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2026–2027
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2023–2027
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Site PI · Recruiting · Phase 1
Allterum Therapeutics, Inc
2026–2028
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Site PI · Recruiting · Phase 1
St. Jude Children's Research Hospital
2024–2027